Sirolimus-induced regression of a large orbital lymphangioma. (2nd January 2019)

• Record Type: Journal Article
• Authors: Lagrèze, Wolf A.; Joachimsen, Lutz; Gross, Nikolai; Taschner, Christian; Rössler, Jochen
• Is Part Of: Orbit. Volume 38:Number 1(2019)
• Page Start: 79
• Page End: 80
• Publication Date: 2019-01-02
• Subjects: Lymphangioma -- lymphatic malformation -- mTOR -- orbit -- sirolimus; Eye-sockets -- Surgery -- Periodicals; Eye-sockets -- Diseases -- Periodicals; Orbit -- surgery -- Periodicals; Orbital Diseases -- Periodicals; 617.7
• DOI: 10.1080/01676830.2018.1436569
• Languages: English
• ISSNs: 0167-6830

Abstract

ABSTRACT: Microcystic lymphatic malformations are difficult to treat surgically, especially when located in the orbital apex. Recently, pharmacologic inhibition of the mTOR pathway by sirolimus was reported as a safe and efficacious treatment option for lymphatic malformations (also known as lymphangiomas). We report the case of a young male patient in which a unilateral, retrobulbar lymphatic malformation regressed to a large extent under treatment with 1 mg sirolimus given orally twice a day over a period of six months.